Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings.

Autor:	Soto-Perez-de-Celis E; Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address: enrique.sotop@incmnsz.mx., Martínez-Peromingo J; Coordinación Sociosanitaria, Consejería de Sanidad, Madrid, Spain., Chávarri-Guerra Y; Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Loh KP; James P Wilmot Cancer Institute, Rochester, NY, USA; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA., Demichelis-Gómez R; Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Rodrigues M; Hospital Israelita Albert Einstein, São Paulo, Brazil., Yabeta F; Hospital General de Agudos Dr Enrique Tornú, Buenos Aires, Argentina., Cengiz Seval G; Hematology Department, Ankara University School of Medicine, Ankara, Turkey., Ilhan O; Hematology Department, Ankara University School of Medicine, Ankara, Turkey., Cordoba R; Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	The lancet. Healthy longevity [Lancet Healthy Longev] 2021 Nov; Vol. 2 (11), pp. e754-e763. Date of Electronic Publication: 2021 Oct 05.
DOI:	10.1016/S2666-7568(21)00182-3
Abstrakt:	In 2020, about 600 000 people aged 65 years and older were diagnosed with a haematological malignancy worldwide, and this number will increase to almost 1 million by 2040, with the largest growth taking place in regions with less developed economies. Health-care systems globally are ill-prepared to face this impending increase in the burden of haematological malignancies among older people, and geriatric oncology and haematology are not properly developed in most low-income and middle-income countries, as well as in many community settings in high-income countries. Here, we provide an overview of the status of geriatric haematology in resource-limited settings, with a focus on health-care systems, educational activities, availability of resource-stratified guidelines, development of clinical programmes, and ongoing research initiatives. We also provide recommendations for the future development of geriatric haematology globally, focusing on the creation of educational activities for health-care providers, fostering research initiatives, improving the inclusion of principles of geriatric care into everyday clinical practice, and building strong international and local partnerships among organisations. Competing Interests: Declaration of interests YC-G reports grants from Roche and personal fees from ASOFARMA, outside the submitted work. RD-G reports grants from Novartis and personal fees from Amgen, AbbVie, Celgene, and Novartis, outside the submitted work. KPL reports personal fees from Pfizer and Seattle Genetics, outside the submitted work. All other authors declare no competing interests. (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu